current therapy options and clinical outcomes analysis in patients with pv
Published 10 years ago • 1.1K plays • Length 17:54Download video MP4
Download video MP3
Similar videos
-
19:03
assessment of novel treatment options for patients with pv
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
19:02
prognostication and initiation of therapy in polycythemia vera: do we have it right?
-
6:07
available treatment options for patients with pv
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
20:50
prognosis and outcome of patients with advanced et and pv
-
12:24
development of long-acting interferon as new therapy for pv and et
-
5:08
current and future treatment options for pv
-
7:08
an overview of et, pv and mf treatment options
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
3:16
the importance of early intervention in young patients with mpns & the role of interferon therapy
-
2:55
pv-aim: using machine learning to predict resistance to hydroxyurea therapy in patients with pv
-
29:27
my view on current and future use of jak inhibitors for et, pv, and mf
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
23:38
why mpns transform to aml
-
16:28
update on long-acting interferons for mpn
-
5:57
advancing therapies for polycythemia vera: enhancing control and quality of life
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
13:09
long-acting interferon: what is the difference?